What is cyproheptadine (mechanism, indications, dosing, side effects, and contraindications)?

Cyproheptadine Overview

Cyproheptadine is a first-generation H1-antihistamine with potent antiserotonergic and anticholinergic properties, primarily used for allergic symptoms but critically important as the preferred antidote for severe serotonin syndrome. 1

Mechanism of Action

Cyproheptadine functions through three distinct pharmacologic pathways:

• Serotonin antagonism: Competitively blocks serotonin at 5-HT2A receptors in the central nervous system, with possible additional effects at 5-HT1A receptors in the midbrain raphe 2
• H1-antihistamine blockade: Provides relief from allergic-type symptoms and rhinorrhea 1
• Anticholinergic activity: Contributes to both therapeutic effects (reduced GI secretions) and adverse effects (sedation, cognitive impairment) 1, 3

Primary Indications

FDA-Approved Uses

• Allergic rhinitis and rhinorrhea: Recommended by the American Academy of Pediatrics for adults and children ≥2 years old, with superior control of rhinorrhea compared to second-generation antihistamines due to anticholinergic effects 1
• Standard adult dosing: 4 mg three times daily 1
• Pediatric formulation: 2 mg/5 mL syrup available 1

Critical Emergency Indication: Serotonin Syndrome

Cyproheptadine is the preferred antidote for severe serotonin syndrome, specifically recommended by the American Academy of Pediatrics over chlorpromazine. 1, 2

Dosing Protocol for Serotonin Syndrome

Adults:

• Initial dose: 12 mg orally 1, 2
• Continuation: 2 mg every 2 hours until symptom improvement 1, 2
• Maintenance: 8 mg every 6 hours 1, 2
• Total daily dose: Typically 12-24 mg 2

Pediatrics:

• Dosing: 0.25 mg/kg per day 1, 2

Administration considerations:

• No parenteral formulation exists 1
• For intubated patients, tablets can be crushed and administered via nasogastric tube 1, 2

Treatment Algorithm for Serotonin Syndrome

Mild cases:

• Discontinue all serotonergic agents 2
• IV fluids, benzodiazepines for agitation, external cooling 2
• Monitor for progression 2

Moderate-to-severe cases (hyperthermia, muscle rigidity, autonomic instability):

• Add cyproheptadine 12 mg initially 1, 2
• Continue 2 mg every 2 hours until resolution 2
• Maintain 8 mg every 6 hours 2
• ICU admission with continuous cardiac monitoring 2

Critical cases (temperature >41.1°C, severe rigidity, organ failure):

• ICU admission mandatory 2
• Intubation and mechanical ventilation 2
• Paralysis with non-depolarizing agents only (avoid succinylcholine due to hyperkalemia/rhabdomyolysis risk) 1, 2
• Cyproheptadine via nasogastric tube 2
• Direct-acting sympathomimetics (phenylephrine, norepinephrine) for hemodynamic instability—avoid indirect agents like dopamine 2

Monitoring Parameters for Serotonin Syndrome

Continue cyproheptadine until complete resolution of the clinical triad:

• Mental status: Return to baseline consciousness 2
• Neuromuscular: Resolution of clonus, hyperreflexia, tremor, and muscle rigidity 2
• Autonomic: Normalization of vital signs, cessation of diaphoresis 2

Laboratory monitoring:

• Serial creatine kinase (detect rhabdomyolysis) 2
• Arterial blood gases (metabolic acidosis) 2
• Serum creatinine (renal failure) 2
• Liver transaminases (hepatic injury) 2
• Coagulation studies (DIC screening) 2

Typical resolution time: Most mild-to-moderate cases resolve within 24-48 hours after discontinuing serotonergic agents and initiating treatment 2

Mortality: Serotonin syndrome carries an 11% mortality rate, with approximately 25% of patients requiring intubation and ICU care 1, 2

Off-Label Indications with Guideline Support

• Mast Cell Activation Syndrome (MCAS): Recommended for gastrointestinal symptoms (diarrhea, nausea) due to dual H1-antihistamine and antiserotonergic properties 1
• Combat-related nightmares/PTSD: American Academy of Sleep Medicine position paper addresses use at 2-24 mg nightly (median effective dose 16-24 mg in veterans), though evidence is conflicting 1
• Appetite stimulation: Demonstrated efficacy in promoting weight gain in adults and children with poor appetite, though not universally authorized for this indication 4, 5

Side Effects and Safety Profile

Common Adverse Effects

• Sedation: Incidence 9-11%, most frequent adverse effect across all age groups 1, 4, 5
• Anticholinergic effects: Dry mouth, dry eyes, constipation, urinary retention 1
• Cognitive impairment: Particularly concerning in elderly patients, may occur without subjective awareness 1, 3
• Performance impairment: Impaired driving ability and school performance 1

Serious Adverse Effects

• Hepatotoxicity: Uncommon to rare (estimated frequency 0.27-1.4 per 1000), with very rare cases of liver failure reported 4
• Hypotension: Can occur when used for serotonin syndrome 2
• Overdose toxicity: Fatalities reported with cyproheptadine intoxication, particularly in combination with other CNS depressants 6

Safety Monitoring

• Hepatic monitoring: Consider liver function tests, especially with prolonged use, given rare but serious hepatotoxicity risk 4
• Cognitive assessment: Particularly important in elderly patients due to anticholinergic burden 1, 3

Contraindications and Precautions

Absolute Contraindications

• Narrow-angle glaucoma: Due to anticholinergic effects 1
• Concurrent use with alcohol or CNS-active substances: Enhances performance impairment 1

High-Risk Populations

• Elderly patients: High-risk medication that should be deprescribed in older adults with cognitive impairment due to anticholinergic effects and sedation 3
• Patients requiring alertness: Avoid in those who need to drive or operate machinery 1

Drug Interactions

• Serotonergic agents: When treating serotonin syndrome, avoid indirect sympathomimetics (dopamine); use direct-acting agents (phenylephrine, norepinephrine) instead 2
• CNS depressants: Enhanced sedation and respiratory depression risk 1

Important Clinical Caveats

Evidence quality for serotonin syndrome: Despite widespread guideline recommendations from the American Academy of Pediatrics, American College of Medical Toxicology, and American Academy of Child and Adolescent Psychiatry, cyproheptadine's efficacy is primarily supported by case reports and case series 2. A 2019 retrospective review of 288 cases showed no significant difference in serious outcomes between patients who received cyproheptadine versus those who did not, though treated patients were generally more severely ill 7. However, expert consensus across multiple major societies supports its use as standard of care for moderate-to-severe serotonin syndrome. 2

Psychiatric effects: The American Academy of Sleep Medicine reports that cyproheptadine may worsen nightmares and restlessness in PTSD patients, and its antiserotonergic activity may cause sedation that can be mistaken for mood improvement 3

Overall safety profile: Cyproheptadine can be considered a safe drug when used appropriately, with mild neurological effects being frequent and serious hepatotoxicity being uncommon to rare 4